Patents Issued in January 14, 2020
-
Patent number: 10532016Abstract: Disclosed herein are zinc-amino acid-tripolyphosphate complexes, oral care and personal care compositions comprising zinc-amino acid-tripolyphosphate complexes, and methods of making and using the same.Type: GrantFiled: December 7, 2018Date of Patent: January 14, 2020Assignee: Colgate-Palmolive CompanyInventors: Zhigang Hao, Dennis Zhang, Donghui Wu, Ravi Subramanyam, Chi-Yuan Cheng, Long Pan, Stanislav Jaracz
-
Patent number: 10532017Abstract: The present disclosure relates to antioxidant compositions comprising a high amount of stabilized neohesperidin dihydrochalcone. The antioxidant compositions may further include additional antioxidants, such as ferulic acid, and tocopherols. The compositions include at least 20 wt. % of one or more water-soluble solvents, such as propanediol, which contribute to the surprising solubility and stability of the compositions. The antioxidant properties of the compositions make them particularly effective for treating and protecting the skin. For example, the compositions are useful for protecting the skin from environmental insult.Type: GrantFiled: December 27, 2016Date of Patent: January 14, 2020Assignee: L'OREALInventors: Lisa Yarhyna Lema, Valerie Robert, Jodi Goldberg, Geoffrey Genesky
-
Patent number: 10532018Abstract: A skin whitening method including: administering to a subject a cosmetic composition including a tranexamic acid-peptide having skin whitening activity selected from the group consisting of Tranexamil-AS, Tranexamil-AT, Tranexamil-AP, Tranexamil-GP, Tranexamil-ES, Tranexamil-KK, Tranexamil-HK, Tranexamil-MY, Tranexamil-GH, Tranexamil-MA, Tranexamil-AH, Tranexamil-CC, Tranexamil-SA, Tranexamil-WA, Tranexamil-WE, Tranexamil-KD, Tranexamil-NA, Tranexamil-TS, Tranexamil-SS, Tranexamil-EC, Tranexamil-TA, Tranexamil-PF, Tranexamil-VS, Tranexamil-VV, Tranexamil-VP, Tranexamil-AA, Tranexamil-PS, Tranexamil-HA, Tranexamil-GK, Tranexamil-KV, Tranexamil-AR, Tranexamil-RP, Tranexamil-PQ, Tranexamil-QG, Tranexamil-PP, Tranexamil-VR, Tranexamil-SV, Tranexamil-ET, Tranexamil-CG and Tranexamil-NT.Type: GrantFiled: June 29, 2017Date of Patent: January 14, 2020Assignee: ANPEP INC.Inventors: Sang Moon Kang, Seock Yeon Hwang, Mi Hye Lim, Chung Park, Eun Jin Shin, Kee-young Lee, Un Kyu Park, Hyun Ji Lim, Dong Hyun Yang, Sang Joo Cha
-
Patent number: 10532019Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.Type: GrantFiled: July 7, 2017Date of Patent: January 14, 2020Assignee: University of Massachusetts LowellInventors: Jonathan Edelson, Robert Nicolosi
-
Patent number: 10532020Abstract: The present embodiments relate to a nail coating having a major advantage in that it enables a nail coating to adhere to a natural nail or uncoated nail for long wear periods without adhesion loss or other signs of breakdown of the coating. Nail topcoats with improved abrasion resistance are also disclosed. Adhesion of a composition for nail coatings be improved by addition of a polyhedral oligomeric silsesquioxane (POSS). Nail coating compositions that benefit from the addition of a POSS include enamels, reactive composition such as those containing acrylates, solventless compositions and water-based compositions.Type: GrantFiled: November 10, 2016Date of Patent: January 14, 2020Assignee: Revlon Consumer Products CorporationInventors: David Valia, Jamie Ellis
-
Patent number: 10532021Abstract: The present invention relates to a non-colouring composition for treating keratin fibres comprising an aqueous dispersion of particles of hybrid hydrophobic acrylic film-forming polymer and a linear block silicone copolymer, and also to a method for treating keratin fibres using such a composition. The composition makes it possible to obtain a coating which is persistent towards shampooing operations, which leaves the treated fibres individualized, with an improved cosmetic feel and a provision of mass and volume.Type: GrantFiled: December 13, 2012Date of Patent: January 14, 2020Assignee: L'OREALInventor: Karen Teboul
-
Patent number: 10532022Abstract: The present invention relates to processes for producing treated olive mill process water (OMPW). In some exemplary embodiments, the treated OMPW is used in the preparation/production of body care products.Type: GrantFiled: July 20, 2015Date of Patent: January 14, 2020Assignees: The United States of America, as represented by The Secretary of Agriculture, McEvoy of Marin, LLCInventors: Rebecca R Milczarek, Jeffrey A Creque, John Bailey, Ellen Roggemann
-
Patent number: 10532023Abstract: Disclosed is a Japanese camellia extract, obtained by extracting Camellia japonica flowers by way of a fatty substance or fatty substance mixture, and to a cosmetic composition including one such extract that has, in particular, a skin-moisturizing effect.Type: GrantFiled: August 1, 2014Date of Patent: January 14, 2020Assignee: CHANEL PARFUMS BEAUTEInventors: Anne Rossignol-Castera, Annabelle L'Hermitte, Gaelle Gendronneau, Serge Holderith, Yannick Maestro
-
Patent number: 10532024Abstract: Compositions for suppressing sebum production in skin (e.g., seborrheic skin), and minimizing glycation in skin (e.g., mature skin) with enhanced UV absorptive properties are described. In particular, the present invention relates to a composition containing a skin benefit agent that includes Lithospermum erythrorhizon. Also, methods of suppressing sebum production in skin (e.g., seborrheic skin) and minimizing glycation in skin (e.g., mature skin) by applying a composition to the skin, wherein the composition comprises an effective amount of a derivative of Lithospermum erythrorhizon are also described.Type: GrantFiled: October 24, 2017Date of Patent: January 14, 2020Assignee: ACCESS BUSINESS GROUP INTERNATIONAL LLCInventors: Rodney A. Velliquette, Kelly M. Glynn, Ernest H. Brumbaugh, Penelope M. Anderson, John F. Rebhun, Stephen R. Missler, Arun Rajgopal
-
Patent number: 10532025Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.Type: GrantFiled: May 18, 2018Date of Patent: January 14, 2020Assignee: Bayer OyInventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti, Tuula Valo, Ina Gröticke, Bernhard Lindenthal, Ulrike Fuhrmann
-
Patent number: 10532026Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.Type: GrantFiled: August 23, 2018Date of Patent: January 14, 2020Assignee: WAKAMOTO PHARMACEUTICAL CO., LTD.Inventors: Takeshi Yamamura, Ayaka Yamamuro, Emi Izukura, Moto Kimura, Tomohiro Otsuka
-
Patent number: 10532027Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.Type: GrantFiled: November 1, 2018Date of Patent: January 14, 2020Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Andrew Bellinger, Shiyi Zhang, Carlo Giovanni Traverso, Robert S. Langer, Stacy Mo, Tyler Grant, Mousa Jafari, Dean Liang Glettig, Angela DiCiccio, Lowell L. Wood, Jr., Philip A. Eckhoff
-
Patent number: 10532028Abstract: A method for preparing solid materials is described. One aspect of the method includes the steps of providing a mixture comprising an organic material in a blend of a solvent and non-solvent for the organic material, distributing the mixture into either droplets or granules, and evaporating the solvent and non-solvent mixture to form particles having an average size of from about 0.5 ?m to about 5000 ?m.Type: GrantFiled: July 28, 2006Date of Patent: January 14, 2020Assignee: ISP INVESTMENTS LLCInventor: John Alfred Doney
-
Patent number: 10532029Abstract: Provided are an alkyl cellulose excellent in formability when added even in a small amount and not causing marked delay in disintegration; a solid preparation comprising it; and a method for producing the solid preparation. More specifically, provided are an alkyl cellulose for use in tableting, the alkyl cellulose having a specific surface area of from 0.5 to 10.0 m2/g as measured by BET method and a solid preparation comprising the alkyl cellulose. Also provided is a method for producing the alkyl cellulose, comprising the steps of: bringing pulp into contact with an alkali metal hydroxide solution to obtain alkali cellulose, reacting the alkali cellulose with an etherifying agent to obtain a first alkyl cellulose, pulverizing the first alkyl cellulose, and depolymerizing the pulverized first alkyl cellulose through hydrolysis with an acid catalyst or through oxidative decomposition with an oxidant to obtain a second alkyl cellulose.Type: GrantFiled: July 27, 2018Date of Patent: January 14, 2020Assignee: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Takuya Yokosawa, Naosuke Maruyama
-
Patent number: 10532030Abstract: Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.Type: GrantFiled: May 30, 2018Date of Patent: January 14, 2020Assignee: LOCL PHARMA, INC.Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
-
Patent number: 10532031Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: November 2, 2018Date of Patent: January 14, 2020Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
-
Patent number: 10532032Abstract: The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. The invention also relates to a rolled compressed collagen carrier for use in the prevention or treatment of injury associated with performing minimally invasive surgery.Type: GrantFiled: October 10, 2017Date of Patent: January 14, 2020Assignee: TAKEDA ASInventors: Wolfgang Schoenhofer, Pernille Dybendal Pedersen, Poul Bertelsen, Henrik Braender, Ingrid Blanka, Henrik Neuschaefer Larsen
-
Patent number: 10532033Abstract: The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.Type: GrantFiled: April 29, 2004Date of Patent: January 14, 2020Assignee: LTS LOHMANN Therapie-Systeme AGInventor: Walter Müller
-
Patent number: 10532034Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed and include those of formula (III): wherein B, R1c, R2c, m, and n are defined herein.Type: GrantFiled: March 25, 2010Date of Patent: January 14, 2020Assignee: Cornell UniversityInventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
-
Patent number: 10532035Abstract: Methods herein are described for improvement in visual function by administering macular carotenoid compositions containing an effective daily dose, to a subject in need thereof. More particularly, methods herein are described and include use of the compositions herein by identifying a subject in need thereof, administering a daily dose of lutein and/or zeaxanthin isomers, comprised of meso-zeaxanthin and R,R zeaxanthin, alone or in combination thereof, the composition also including at least one food grade excipient, and evaluating visual performance. The subject is exposed to light of variable wavelengths and intensity and is suffering from visual fatigue. The composition improves contrast sensitivity, glare performance, photo stress recovery, and/or macular pigment optical density, and thus alleviates visual fatigue. The composition is safe for human and other animals for consumption and can be used for improvement in visual health in the subject, when administered in an effective amount.Type: GrantFiled: March 25, 2016Date of Patent: January 14, 2020Assignee: OmniActive Health Technologies LimitedInventors: Jayant Deshpande, Vijaya Juturu, Khadija Ghanam, Lynda Doyle
-
Patent number: 10532036Abstract: A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol.Type: GrantFiled: April 5, 2013Date of Patent: January 14, 2020Assignee: AFT Pharmaceuticals LimitedInventor: Hartley Campbell Atkinson
-
Patent number: 10532037Abstract: A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 50 mg to 425 mg per oral combination drug formulation.Type: GrantFiled: March 5, 2019Date of Patent: January 14, 2020Assignee: ARSTAT, Inc.Inventor: Arkady Rubin
-
Patent number: 10532038Abstract: The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.Type: GrantFiled: August 28, 2013Date of Patent: January 14, 2020Assignees: FUNDACÍON CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC), HOSPITAL CLÍNIC DE BARCELONAInventors: Borja Ibáñez Cabeza, Ana García-Álvarez, Valentín Fuster Carulla
-
Patent number: 10532039Abstract: A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.Type: GrantFiled: January 3, 2017Date of Patent: January 14, 2020Assignee: The William M. Yarbrough FoundationInventor: Michael E. Silver
-
Patent number: 10532040Abstract: The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and/or skin cancer in a mammal.Type: GrantFiled: November 19, 2012Date of Patent: January 14, 2020Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Ann M. Bode, Young-Yeon Cho, Zigang Dong, Dong Joon Kim
-
Patent number: 10532041Abstract: A method is disclosed for making a pharmaceutical composition for pulmonary administration comprising co-jet milling glycopyrrolate and magnesium stearate, wherein the co-jet milled glycopyrrolate and magnesium stearate is then subjected to a conditioning step which includes exposure of the co-jet milled glycopyrrolate and magnesium stearate to humidity. A composition made by this method is also disclosed.Type: GrantFiled: September 9, 2015Date of Patent: January 14, 2020Assignee: Vectura LimitedInventor: Fergus Manford
-
Patent number: 10532042Abstract: Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: December 21, 2017Date of Patent: January 14, 2020Assignee: Amgen Inc.Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
-
Patent number: 10532043Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.Type: GrantFiled: August 15, 2019Date of Patent: January 14, 2020Assignee: Ankh Life Sciences LimitedInventors: Gene H. Zaid, Thomas W. Burgoyne
-
Patent number: 10532044Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.Type: GrantFiled: February 11, 2019Date of Patent: January 14, 2020Assignee: CHEMOCENTRYX, INC.Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
-
Patent number: 10532045Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.Type: GrantFiled: December 18, 2014Date of Patent: January 14, 2020Assignee: Signpath Pharma, Inc.Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard
-
Patent number: 10532046Abstract: The present disclosure relates to compositions that are useful in the delivery of various materials. In particular, the compositions comprise a suspension wherein an internal phase material is surrounded by an external phase material. The internal phase specifically can be a hydrophilic material, and the external phase specifically can be a hydrophobic material. The materials are combined so that the internal phase is substantially encapsulated by the external phase such that release can be controlled in relation to osmotic pressure differentials. The suspension can be combined with a carrier, and various systems and products can be formed with the suspension and optional carrier, such as oral strips, spray delivery systems, smokeless tobacco products, aerosol delivery devices, cigarettes, and packaging.Type: GrantFiled: December 3, 2015Date of Patent: January 14, 2020Assignee: Niconovum USA, Inc.Inventors: James William Rogers, Michael F. Davis, Percy D. Phillips, Karen V. Taluskie, Stephen Benson Sears, Ercilia Hernandez Garcia
-
Patent number: 10532047Abstract: The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.Type: GrantFiled: May 16, 2019Date of Patent: January 14, 2020Assignee: FORMA Therapeutics, Inc.Inventor: George P. Luke
-
Patent number: 10532048Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: GrantFiled: July 5, 2018Date of Patent: January 14, 2020Assignee: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 10532049Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.Type: GrantFiled: February 26, 2019Date of Patent: January 14, 2020Assignee: Pharmaceutical Industries LimitedInventors: Alpesh Goyani, Deepak Singodia, Bhaskar Pallerla, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
-
Patent number: 10532050Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.Type: GrantFiled: April 8, 2014Date of Patent: January 14, 2020Assignee: Lixte Biotechnology, Inc.Inventors: John S. Kovach, Mickey L. Wells
-
Patent number: 10532051Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.Type: GrantFiled: October 5, 2015Date of Patent: January 14, 2020Assignee: CHEMOCENTRYX, INC.Inventors: Karen Ebsworth, Yu Wang, Yibin Zeng, Penglie Zhang, Joanne Tan
-
Patent number: 10532052Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.Type: GrantFiled: November 12, 2015Date of Patent: January 14, 2020Assignee: Merck Patent GmbHInventors: Friedhelm Bladt, Manja Friese-Hamim
-
Patent number: 10532053Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells. In Formula I, the variables are as described herein.Type: GrantFiled: March 17, 2016Date of Patent: January 14, 2020Assignee: Guangdong Zhongsheng Pharmaceutical Co., LtdInventors: Lijuan Chen, Chaofeng Long, Xiaoxin Chen, Zhuowei Liu, Haoyu Ye, Chenshi Xie
-
Patent number: 10532054Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: GrantFiled: September 20, 2017Date of Patent: January 14, 2020Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 10532056Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.Type: GrantFiled: June 29, 2016Date of Patent: January 14, 2020Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
-
Patent number: 10532057Abstract: The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon oral administration, for the treatment or prevention of levodopa-induced dyskinesia. The present invention also provides an improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (I) in combination with ievodopa.Type: GrantFiled: August 26, 2016Date of Patent: January 14, 2020Assignee: Prexton Therapeutics SAInventors: Delphine Charvin, François Conquet
-
Patent number: 10532058Abstract: The present invention relates to a highly convergent method for the synthesis and purification of ceftolozane and intermediates starting from 7-aminocephaiosporanic acid (7-ACA).Type: GrantFiled: September 7, 2016Date of Patent: January 14, 2020Assignee: Sandoz AGInventors: Michael Fischer, Wolfgang Felzmann, Ronny Huetz, Martin Langner, Birgit Endl
-
Patent number: 10532059Abstract: This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.Type: GrantFiled: February 21, 2018Date of Patent: January 14, 2020Assignee: TherapeuticsMD, Inc.Inventors: Annette Shadiack, Peter H. R. Persicaner, Philip B. Inskeep, Thorsteinn Thorsteinsson, Frederick D. Sancilio, Jason D. Legassie
-
Patent number: 10532060Abstract: The present invention relates to a serum LDL cholesterol lowering edible product containing plant sterol ester and/or plant stanol ester, and especially to a dietary supplement product.Type: GrantFiled: March 3, 2015Date of Patent: January 14, 2020Assignee: Raisio Nutrition Ltd.Inventors: Ingmar Wester, Paivi Kuusisto, Jouni Reijo Kalevi Niemela, Tuula Forbom, Kurt I. Draget, Andrzej Siwek, Kamilla Lundhaug, Jan Erik Olsen
-
Patent number: 10532061Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.Type: GrantFiled: September 6, 2018Date of Patent: January 14, 2020Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 10532063Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.Type: GrantFiled: June 28, 2018Date of Patent: January 14, 2020Assignee: The Procter & Gamble CompanyInventors: Steven Ray Gilbert, Edward Paul Fitch, V, Derrick Ho, Daniel Jerome White, Jr., Adam Michael Tunis
-
Patent number: 10532064Abstract: Aminobisphosphonate pamidronate (PAM) can control Epstein-Barr virus (EBV) associated disorders in humanized mice through a V?9V?2-T-cell dependent mechanism. This suggests a strong potential for a therapeutic approach using PAM to boost human V?9V?2-T-cell immunity against EBV associated disorders, such as the lymphoproliferative disease (LPD), posttransplant lymphoproliferative disorder (PLPD), Hodgkin's disease, Burkitt's lymphoma, and nasopharyngeal carcinoma (NPC).Type: GrantFiled: August 12, 2015Date of Patent: January 14, 2020Assignee: The University of Hong KongInventors: Wenwei Tu, Zheng Xiang, Yinping Liu
-
Patent number: 10532065Abstract: The novel bisphosphonic acid ester derivatives represented by the following formula (1): Y—Cy—(NH)m—(CH2)n—C(X)(PO(OR1)(OR2))2??(1) wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.Type: GrantFiled: December 18, 2015Date of Patent: January 14, 2020Assignee: NAGASAKI UNIVERSITYInventors: Yoshimasa Tanaka, Kenji Matsumoto, Kosuke Hayashi, Yuki Sakai, Nagahiro Minato
-
Patent number: 10532066Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.Type: GrantFiled: December 4, 2017Date of Patent: January 14, 2020Assignee: National Jewish HealthInventors: Dennis R. Voelker, Mari Numata-Nakamura
-
Patent number: 10532067Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: October 5, 2017Date of Patent: January 14, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl